BTK Inhibitor-Associated Adverse Events

Author(s):

Kirollos Hanna, PharmD, BCPS, BCOP,Brandon Dyson, PharmD, BCPS

The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.

Now Viewing

EP: 1.BTK Inhibitor-Associated Adverse Events

EP: 2.Managing Adverse Events and Supportive Care Measures in CLL Treatment

EP: 3.Impact of Dose Modifications on CLL Treatment

EP: 4.Considerations for Dose Modifications

EP: 5.Economic Impact of Dose Modifications on CLL Management

EP: 6.Factors to Consider When Switching Therapies

EP: 7.Medicare Part D Smoothing Program: Impact on Access and Adherence

Video content above is prompted by the following:

How has the understanding of adverse events associated with Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment evolved, and what are the primary classwide adverse events?